New operating procedures at CSIRO
08 April, 2014CSIRO's chief executive, Dr Megan Clark, has provided an update into new operating arrangements at the organisation. The changes are aimed at making things easier for both staff and those doing business with CSIRO.
Rescop opens UK and Australian offices
24 March, 2014Rescop (Regulatory System Compliance Partners), an international life sciences service and solution provider, has announced the opening of new offices in the UK and Australia.
Cogstate test to be used in paediatric clinical trial
13 February, 2014Cognitive assessment and training company Cogstate has announced that its technology will be used in a large paediatric clinical trial in the United States.
Anton Paar process instrumentation joins MEP
05 February, 2014From 1 February, MEP Instruments incorporates the Anton Paar process instrumentation portfolio and certified support, suitable for critical production processes.
Trajan joins BioMelbourne Network
03 February, 2014Trajan Scientific and Medical is now a member of BioMelbourne Network, an industry forum for the leaders of the Victorian biotechnology industry.
University of Melbourne and Sanofi Pasteur to develop human vaccines
22 January, 2014Sanofi Pasteur has signed a vaccine development agreement with the University of Melbourne. The alliance was facilitated by UoM Commercial, the university's commercial engagement services company.
US EPA contracts Stemina for toxicology tests
10 January, 2014Stemina Biomarker Discovery, a company whose cell-based tests combine stem cells and metabolomics, has been awarded a contract by the US Environmental Protection Agency (EPA) under its ToxCast initiative.
Ascend and 3M to collaborate on cancer vaccine
02 December, 2013US multinational 3M Drug Delivery Systems has partnered with Melbourne-based immunotherapy biotech Ascend Biopharmaceuticals to work on cancer vaccines targeting solid tumour types which incorporate aspects of both companies' technology.
Fred Hollows Foundation and International Diabetes Federation to tackle diabetic blindness
29 November, 2013The Fred Hollows Foundation has signed up to a 10-year partnership with the International Diabetes Federation to tackle a complication of the disease that can lead to blindness. The agreement was announced just days before the start of the World Congress on Diabetes in Melbourne, to be attended by over 10,000 delegates and 400 exhibitors from 2-6 December.
Strategic agreement to help fix the body's leaky pipes
07 November, 2013Danish biotechnology company Mirrx Therapeutics and Sydney's Centenary Institute of Cancer Medicine and Cell Biology have executed a strategic collaboration and commercialisation agreement to discover and develop therapeutic oligonucleotide drug candidates targeting vascular endothelial cadherin (VE-cadherin).
LabGear life sciences equipment and consumables
06 August, 2013LabGear Australia is a supplier of equipment and consumables to the Australian life science market. The company’s aim is to offer a select range of high-quality products backed up by a high level of after-sales service and support.
Mega Lifesciences to open mega manufacturing plant
06 June, 2013Pharmaceuticals company Mega Lifesciences is expanding its Australian business operations with the opening of an $8 million manufacturing plant in Pakenham, Victoria.
Qiagen adds biomarkers for personalised healthcare companion diagnostics
03 June, 2013Qiagen has announced two agreements adding promising new biomarkers involving glioblastoma, lymphoma and other cancers to the company’s expanding portfolio of potential companion diagnostics.
UWA forms spin-out company to develop nanoparticle cancer drugs
16 May, 2013The University of Western Australia (UWA) and Yuuwa Capital LP have set up a new spin-out company, Eridan Technology, to commercialise nanoparticle technology for drug delivery applications.
CPR launches ligand binding assay service for large molecules
02 May, 2013Clinical research company CPR Pharma Services has launched a new laboratory in Adelaide to provide a ligand binding assay service for biomarkers, monoclonal antibodies, biosimilars and biologics in early- and late-phase clinical trials.
